trending Market Intelligence /marketintelligence/en/news-insights/trending/rrDLN6tlLG8h8BGANjdaAA2 content esgSubNav
In This List

Aerie Pharmaceuticals completes $10M Avizorex Pharma acquisition

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aerie Pharmaceuticals completes $10M Avizorex Pharma acquisition

Aerie Pharmaceuticals Inc. has completed its acquisition of Avizorex Pharma SL in an all-cash deal worth $10 million.

The Durham, N.C.-based company previously said the acquisition will expand its eye disease product portfolio.

Avizorex's therapy AVX-012 has shown positive results during a phase 2a clinical trial in patients with dry eye disease. The drug acts on the TRPM8 protein, which is believed to play a role in treating dry eye disease, a common condition that occurs when tears are not able to provide adequate lubrication for the eyes.

Aerie also acquired the rights to other compounds that target TRPM8 through the Avizorex deal.